• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于实验动物长效药物治疗的皮下植入物可能会产生意外的药物储存库。

Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

作者信息

Guarnieri Michael, Tyler Betty M, Detolla Louis, Zhao Ming, Kobrin Barry

机构信息

Department of Neurological Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Department of Pathology and Medicine, School of Medicine, Division of Infectious Diseases and Public Health, The Program of Comparative Medicine, University of Maryland, Baltimore, Maryland, USA.

出版信息

J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315.

DOI:10.4103/0975-7406.124315
PMID:24459402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3895292/
Abstract

BACKGROUND

Long-acting therapy in laboratory animals offers advantages over the current practice of 2-3 daily drug injections. Yet little is known about the disintegration of biodegradable drug implants in rodents.

OBJECTIVE

Compare bioavailability of buprenorphine with the biodegradation of lipid-encapsulated subcutaneous drug pellets.

METHODS

Pharmacokinetic and histopathology studies were conducted in BALB/c female mice implanted with cholesterol-buprenorphine drug pellets.

RESULTS

Drug levels are below the level of detection (0.5 ng/mL plasma) within 4-5 days of implant. However, necroscopy revealed that interstitial tissues begin to seal implants within a week. Visual inspection of the implant site revealed no evidence of inflammation or edema associated with the cholesterol-drug residue. Chemical analyses demonstrated that the residues contained 10-13% of the initial opiate dose for at least two weeks post implant.

DISCUSSION

The results demonstrate that biodegradable scaffolds can become sequestered in the subcutaneous space.

CONCLUSION

Drug implants can retain significant and unintended reservoirs of drugs.

摘要

背景

在实验动物中,长效治疗相较于当前每日2至3次注射药物的做法具有优势。然而,关于可生物降解药物植入物在啮齿动物体内的降解情况,人们了解甚少。

目的

比较丁丙诺啡的生物利用度与脂质包裹皮下药物微丸的生物降解情况。

方法

对植入胆固醇 - 丁丙诺啡药物微丸的BALB/c雌性小鼠进行药代动力学和组织病理学研究。

结果

植入后4至5天内,药物水平低于检测限(血浆0.5 ng/mL)。然而,尸检显示间质组织在一周内开始封闭植入物。对植入部位的目视检查未发现与胆固醇 - 药物残留相关的炎症或水肿迹象。化学分析表明,植入后至少两周,残留物含有初始阿片类药物剂量的10 - 13%。

讨论

结果表明可生物降解支架可在皮下空间被隔离。

结论

药物植入物可保留大量意外的药物储存库。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b01/3895292/a70945b45b3e/JPBS-6-38-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b01/3895292/ff2ce27c1cb6/JPBS-6-38-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b01/3895292/a70945b45b3e/JPBS-6-38-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b01/3895292/ff2ce27c1cb6/JPBS-6-38-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b01/3895292/a70945b45b3e/JPBS-6-38-g002.jpg

相似文献

1
Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.用于实验动物长效药物治疗的皮下植入物可能会产生意外的药物储存库。
J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315.
2
Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.大鼠皮下植入胆固醇-甘油三酯-丁丙诺啡混悬液
J Vet Med. 2017;2017:3102567. doi: 10.1155/2017/3102567. Epub 2017 Apr 9.
3
Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.小鼠皮下注射丁丙诺啡-胆固醇-甘油三酯粉末植入物
J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27.
4
Pharmacokinetic comparison of three delivery systems for subcutaneous testosterone administration in female mice.三种皮下睾酮给药系统在雌性小鼠中的药代动力学比较。
Gen Comp Endocrinol. 2022 Oct 1;327:114090. doi: 10.1016/j.ygcen.2022.114090. Epub 2022 Jun 24.
5
A Long-Term Study of a Lipid-Buprenorphine Implant in Rats.大鼠脂质-丁丙诺啡植入剂的长期研究。
J Vet Med. 2018 Jul 9;2018:2616152. doi: 10.1155/2018/2616152. eCollection 2018.
6
Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.抗逆转录病毒替诺福韦艾拉酚胺富马酸盐药物洗脱皮下植入物的设计。
Pharm Res. 2020 Apr 15;37(4):83. doi: 10.1007/s11095-020-2777-2.
7
Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.
Xenobiotica. 1985 Apr;15(4):287-97. doi: 10.3109/00498258509045363.
8
Buprenorphine implants: a model for expedited development and approval of new drugs.丁丙诺啡植入剂:加速新药研发和审批的范例。
Curr Med Res Opin. 2021 Jan;37(1):83-88. doi: 10.1080/03007995.2020.1840971. Epub 2020 Nov 24.
9
Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat.大鼠皮下植入吗啡微丸后的长期耐受性、依赖性及戒断反应
Eur J Pharmacol. 1994 Feb 21;253(1-2):45-51. doi: 10.1016/0014-2999(94)90755-2.
10
A long-acting buprenorphine delivery system.一种长效丁丙诺啡给药系统。
Pharmacol Biochem Behav. 1983 Mar;18(3):471-4. doi: 10.1016/0091-3057(83)90472-0.

引用本文的文献

1
Innovative Chitosan-Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits.用于恩诺沙星控释的新型壳聚糖制剂:家兔体内药代动力学分析
Vet Med Sci. 2025 Nov;11(6):e70618. doi: 10.1002/vms3.70618.
2
Chronic palmitoylethanolamide administration slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer's disease.慢性给予棕榈酰乙醇胺缓释皮下微丸可促进Tg2576阿尔茨海默病小鼠模型的神经保护并减轻神经炎症。
Front Cell Neurosci. 2025 Apr 17;19:1571428. doi: 10.3389/fncel.2025.1571428. eCollection 2025.
3
Long-term dissolution of thermo- and pH-responsive, F magnetic resonance-traceable and injectable polymer implants.

本文引用的文献

1
Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research.工程化固体脂质纳米粒用于改善药物递送:转化研究的前景与挑战。
Drug Deliv Transl Res. 2012 Aug;2(4):238-53. doi: 10.1007/s13346-012-0088-9.
2
Safety and efficacy of buprenorphine for analgesia in laboratory mice and rats.布比卡因在实验小鼠和大鼠中的镇痛安全性和疗效。
Lab Anim (NY). 2012 Nov;41(11):337-43. doi: 10.1038/laban.152.
3
Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals.
热响应和pH响应、具有磁共振可追踪性且可注射的聚合物植入物的长期溶解
Nanoscale Adv. 2024 Apr 8;6(12):3041-3051. doi: 10.1039/d4na00212a. eCollection 2024 Jun 11.
4
Investigation of the In Vitro and In Vivo Biocompatibility of a Three-Dimensional Printed Thermoplastic Polyurethane/Polylactic Acid Blend for the Development of Tracheal Scaffolds.用于气管支架开发的三维打印热塑性聚氨酯/聚乳酸共混物的体外和体内生物相容性研究
Bioengineering (Basel). 2023 Mar 23;10(4):394. doi: 10.3390/bioengineering10040394.
5
Clinical Management of Pain in Rodents.啮齿动物疼痛的临床管理
Comp Med. 2019 Dec 1;69(6):468-489. doi: 10.30802/AALAS-CM-19-000048. Epub 2019 Dec 10.
6
A Long-Term Study of a Lipid-Buprenorphine Implant in Rats.大鼠脂质-丁丙诺啡植入剂的长期研究。
J Vet Med. 2018 Jul 9;2018:2616152. doi: 10.1155/2018/2616152. eCollection 2018.
7
A novel surgical technique for a rat subcutaneous implantation of a tissue engineered scaffold.一种用于大鼠皮下植入组织工程支架的新型手术技术。
Acta Histochem. 2018 Apr;120(3):282-291. doi: 10.1016/j.acthis.2018.02.010. Epub 2018 Mar 5.
8
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.普罗布啡(丁丙诺啡植入剂):治疗阿片类药物依赖的一个有前景的候选药物。
Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134. doi: 10.1177/2045125316681984. Epub 2016 Dec 19.
9
Evaluation of buprenorphine hydrochloride Pluronic(®) gel formulation in male C57BL/6NCrl mice.盐酸丁丙诺啡普朗尼克(®)凝胶制剂在雄性C57BL/6NCrl小鼠中的评价。
Lab Anim (NY). 2016 Sep 21;45(10):370-9. doi: 10.1038/laban.1106.
10
Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.小鼠皮下注射丁丙诺啡-胆固醇-甘油三酯粉末植入物
J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27.
《实验动物饲养与使用指南》第八版中的疼痛管理标准。
J Am Assoc Lab Anim Sci. 2012 May;51(3):322-8.
4
FELASA guidelines and recommendations.FELASA指南与建议。
J Am Assoc Lab Anim Sci. 2012 May;51(3):311-21.
5
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.脑癌内放治疗用溴化乙锭植入剂(BCNU 晶片)在高级别脑胶质瘤患者中的应用:一系列临床病例的临床和影像学考虑。
Acta Neurochir (Wien). 2010 Nov;152(11):1923-31. doi: 10.1007/s00701-010-0759-6. Epub 2010 Aug 13.
6
Morbidity and mortality rates associated with serial bleeding from the superficial temporal vein in mice.与小鼠颞浅静脉反复出血相关的发病率和死亡率。
Lab Anim (NY). 2010 Aug;39(8):236-40. doi: 10.1038/laban0810-236.
7
In-vitro and in-vivo characterization of a buprenorphine delivery system.丁丙诺啡给药系统的体外和体内特性研究
J Pharm Pharmacol. 2006 Mar;58(3):295-302. doi: 10.1211/jpp.58.3.0002.
8
In vitro release of clomipramine HCl and buprenorphine HCl from poly adipic anhydride (PAA) and poly trimethylene carbonate (PTMC) blends.盐酸氯米帕明和盐酸丁丙诺啡从聚己二酸酐(PAA)与聚三亚甲基碳酸酯(PTMC)共混物中的体外释放。
J Biomed Mater Res A. 2005 Oct 1;75(1):185-91. doi: 10.1002/jbm.a.30398.
9
A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain.单剂量脂质体包裹的羟吗啡酮或吗啡在神经性疼痛动物模型中可提供长期镇痛效果。
Comp Med. 2003 Jun;53(3):280-7.
10
Enzyme immunoassay validation for the detection of buprenorphine in urine.用于检测尿液中丁丙诺啡的酶免疫测定法验证
J Anal Toxicol. 2003 Mar;27(2):103-5. doi: 10.1093/jat/27.2.103.